World’s first Artificial Intelligence (AI) technology to predict heart disease
A revolutionary new medical device, that can predict coronary artery disease, which is the number one cause of death in the UK and globally, has been developed by Ultromics, a health-tech spin-out from the University of Oxford.
The pioneering technology, called EchoGo Pro, is the first to successfully use AI to make predictions about coronary heart disease (CAD) risk through ultrasound analysis – the primary imaging test to diagnose heart disease, with a staggering 60,000 Stress Echo scans performed in the UK each year.
EchoGo Pro is able to deliver heart disease prognosis to hospital sites through its secure cloud system, built in partnership with the NHS, based on thousands of past clinical exams. The system automatically analyses ultrasound images and applies artificial intelligence to identify disease, analysing thousands of data points, compared to 5-6 indicators in traditional visual inspection. The system is able to generate a report in minutes and send a prognosis to the doctor treating the patient.
“The CE mark for EchoGo Pro is an important time in the battle against heart disease where real progress is being made to help improve patient outcomes and prevent heart disease. Leveraging AI technology means we can more accurately predict heart disease and optimise care pathways – to help make valuable cost and time savings for healthcare systems at this time when they are already stretched and in much need of support.”
Professor Paul Leeson, Head of the Oxford Cardiovascular Clinical Research Facility, who co-founded Ultromics
Read more, HERE.